According to the World Health Organization (WHO), over 422 million people globally live with diabetes, while obesity has nearly tripled since 1975, with more than 1 billion individuals affected, significantly increasing demand for effective GLP-1-based therapeutic interventions worldwide
In the rest of this letter for StayCurious Metabolism Premium members, we will dive into: How people are using tesamorelin in the real world (biohackers, Silicon Valley, etc.) Dosing and protocols , including frequency, cycling, timing, and what to track to optimize benefits while minimizing risk
When shedding begins on GLP-1 therapy, I look for timing, diet, stress, and nutrient patterns before anything else
A study reported that LCAR showed anti-inflammatory and antioxidant properties through the adenosine monophosphate-activated protein kinase (AMPK)/ serine/threonine kinase (AKT)/ nuclear factor-B (NF-) signaling pathway in rats brain tissue (Salama and Elgohary 2021)
